Fixed combination of latanoprost and timolol in the long-term treatment of patients with normal-tension glaucoma

Close metadata

Recommended articles:

Comparison of the effectiveness and safety of glaucoma drugs in the therapy of primary open-angle glaucoma. Russian Annals of Ophthalmology. 2023;(6):101-108

Efficacy and safety of the fixed combination of dorzolamide/timolol (Dorzotimol) in primary open-angle glaucoma. Russian Annals of Ophthalmology. 2024;(5):125-129

The most well-studied and widely prescribed fixed-combination drug for open-angle glaucoma is latanoprost/timolol. Its significant hypotensive effect is especially important in challenging cases, among which are patients with normal-tension glaucoma. With long life expectancy and the constant need for treatment, requirements are high for both the effectiveness of the drug and its tolerability. This paper presents a follow-up of 7 patients with normal-tension glaucoma who have been using the fixed combination of latanoprost/timolol for 10 years. All patients showed very good tolerability to the drug and their quality of life was preserved. A moderate rate of disease progression according to static perimetry was noted in one case. A mild degree of dry eye syndrome according to the OSDI questionnaire and an objective assessment of the state of the ocular surface was observed in one patient. The latanoprost/timolol fixed combination is a well-tolerated, highly effective and safe long-term treatment choice for normal-tension glaucoma.

Keywords:

normal tension glaucoma

fixed combinations

latanoprost

timolol

long-term use

Authors:

Karlova E.V.

Samara Regional Clinical Ophthalmological Hospital named after T.I. Eroshevsky

Zolotarev A.V.

Samara State Medical University, Department of Ophthalmology;
Samara Regional Clinical Ophthalmological Hospital named after T.I. Eroshevsky

Received:

25.04.2022

Accepted:

07.05.2022

List of references:

Oftal’mologiya. Natsional’noe rukovodstvo [Ophthalmology. National guideline]. Eds Avetisov SE, Egorov EA, Moshetova LK, Neroev VV, Takhchidi KhP. M.: GEOTAR-Media; 2018. (In Russ.).
Konstas AG, Schmetterer L, Costa VP, et al. Current and emerging fixed combination therapies in glaucoma: a safety and tolerability review. Expert Opin Drug Saf. 2020;19(11):1445-1460. https://doi.org/10.1080/14740338.2020.1826928
Xing Y, Zhu L, Zhang K, Huang S. The efficacy of the fixed combination of latanoprost and timolol versus other fixed combinations for primary open-angle glaucoma and ocular hypertension: A systematic review and meta-analysis. PLoS One. 2020;15(2):e0229682. Epub 2020 Feb 27. https://doi.org/10.1371/journal.pone.0229682
Nacional’noe rukovodstvo po glaukome dlya praktivuyushchih vrachej [National guideline for glaucoma for practitioners]. M.: GEOTAR-Media; 2019. (In Russ.).
Instruction for use: Xalacom. P N013924/01. (In Russ.).
Klinicheskie rekomendacii. Glaukoma pervichnaya otkrytougol’naya — 2020. Utverzhdeny Minzdravom RF [Clinical guidelines. Primary open-angle glaucoma — 2020. Approved by the Ministry of Health of the Russian Federation]. (In Russ.).
Xing Y, Jiang FG, Li T. Fixed combination of latanoprost and timolol vs the individual components for primary open angle glaucoma and ocular hypertension: a systematic review and meta-analysis. Int J Ophthalmol. 2014; 7(5):879-890. Epub 2014 Oct 18. https://doi.org/10.3980/j.issn.2222-3959.2014.05.26
Cheng JW, Cheng SW, Gao LD, Lu GC, Wei RL. Intraocular pressure-lowering effects of commonly used fixed-combination drugs with timolol: a systematic review and meta-analysis. PLoS One. 2012;7(9):e45079. https://doi.org/10.1371/journal.pone.0045079
Kazanfarova MA, Alekseev IB, Lindenbraten AL, Kochergin SA. Improving effectiveness of glaucoma screening during prophylactic medical examinations: current approaches. Russian Journal of Clinical Ophthalmology = RMZh. Klinicheskaja oftal’mologija. 2019;19(3):122-127. (In Russ.). https://doi.org/10.32364/2311-7729-2019-19-3-122-127
Rykov SA, Vitovskaya OP. Screening of POAG — pros and cons. Invitation for discussion. Russian Journal of Clinical Ophthalmology = RMZh. Klinicheskaja oftal’mologija. 2010;(4):131-134. (In Russ.).
Lazcano-Gomez G, Ramos-Cadena MLA, Torres-Tamayo M, Hernandez de Oteyza A, Turati-Acosta M, Jimenez-Román J. Cost of glaucoma treatment in a developing country over a 5-year period. Medicine (Baltimore). 2016;95(47):e5341. https://doi.org/10.1097/MD.0000000000005341
Cheng JW, Cai JP, Wei RL. Meta-analysis of medical intervention for normal tension glaucoma. Ophthalmology. 2009;116(7):1243-1249. https://doi.org/10.1016/j.ophtha.2009.01.036
Kim TW, Kim M, Lee EJ, Jeoung JW, Park KH. Intraocular pressure-lowering efficacy of dorzolamide/timolol fixed combination in normal-tension glaucoma. J Glaucoma. 2014;23(5):329-332. https://doi.org/10.1097/IJG.0b013e3182741f4d
Kim JM, Kim TW, Kim CY, Kim HK, Park KH. Comparison of the intraocular pressure-lowering effect and safety of brimonidine/timolol fixed combination and 0.5% timolol in normal-tension glaucoma patients. Jpn J Ophthalmol. 2016;60(1):20-26. https://doi.org/10.1007/s10384-015-0420-2
The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol. 1998;126(4):498-505. https://doi.org/10.1016/s0002-9394(98)00272-4
Leske MC, Heijl A, Hyman L, et al. Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology. 2007;114(11):1965-1972. https://doi.org/10.1016/j.ophtha.2007.03.016
Takagi Y, Santo K, Hashimoto M, Fukuchi T. Ocular hypotensive effects of prostaglandin analogs in Japanese patients with normal-tension glaucoma: a literature review. Clin Ophthalmol. 2018;12:1837-1844. Epub 2018 Sep 21. https://doi.org/10.2147/OPTH.S166657
Erichev VP, Tumanov VP, Panyushkina LA, Fedeorov AA. Comparative analysis of morphological changes in the optic centers in patients with glaucoma and Alzheimer’s disease. Natsional’nyi zhurnal glaukoma. 2014;13(3):5-13. (In Russ.).
Maurano STP, da Silva DJ, Ávila MP, Magacho L. Cognitive evaluation of patients with glaucoma and its comparison with individuals with Alzheimer’s disease. Int Ophthalmol. 2018;38(5):1839-1844. https://doi.org/10.1007/s10792-017-0658-4
Mercer R, Mathew RG, Henein C. Infographic: Collaborative Normal-Tension Glaucoma Study (CNTGS). Eye (Lond). 2021;35(10):2667-2668. https://doi.org/10.1038/s41433-021-01431-2
Wang R, Tang Z, Sun X, et al. White Matter Abnormalities and Correlation With Severity in Normal Tension Glaucoma: A Whole Brain Atlas-Based Diffusion Tensor Study. Invest Ophthalmol Vis Sci. 2018;59(3):1313-1322. https://doi.org/10.1167/iovs.17-23597
Nasaruddin NH, Yusoff AN, Kaur S. Functional MRI Characteristics in Visual Cortex (BA 17, 18 and 19) Corresponding to the visual field of normal, glaucoma suspect (GS) and primary open angle glaucoma (POAG) patients. Jurnal Sains Kesihatan Malaysia. 2017;15:27-32. https://doi.org/10.17576/JSKM-2017-1501-04
Petrov SYu. Modern view on normal-tension glaucoma. The Russian Annals of Ophthalmology = Vestnik oftal’mologii. 2020;136(6):57-64. (In Russ.).
Kurysheva NI. Long-term use of latanoprost in the treatment of glaucoma. The Russian Annals of Ophthalmology = Vestnik oftal’mologii. 2020;136(2):125-132. (In Russ.).
Kurysheva NI, Azizova OA, Piryazev AP. A Comparative Study into Antioxidant Activity of Fixed Combinations in Topical Glaucoma Treatment. Rossiiskii oftal’mologicheskii zhurnal. 2013;2(6):41-44. (In Russ.).
Fuma S, Shimazawa M, Imamura T, et al. Neuroprotective Effect of Ocular Hypotensive Drugs: Latanoprost/Timolol in Combination Are More Effective than Each as Monotherapy in RGC-5. Biol Pharm Bull. 2016;39(2): 192-198. https://doi.org/10.1248/bpb.b15-00584
Shoji T, Sato H, Mizukawa A, et al. Hypotensive effect of latanoprost/timolol versus travoprost/timolol fixed combinations in NTG patients: a randomized, multicenter, crossover clinical trial. Invest Ophthalmol Vis Sci. 2013; 54(9):6242-6247. Epub 2013 Sep 17. https://doi.org/10.1167/iovs.13-11942
Igarashi R, Togano T, Sakaue Y, Yoshino T, Ueda J, Fukuchi T. Effect on intraocular pressure of switching from latanoprost and travoprost monotherapy to timolol fixed combinations in patients with normal-tension glaucoma. J Ophthalmol. 2014;2014:720385. https://doi.org/10.1155/2014/720385
Suzuki K, Otsuka N, Hizaki H, Hashimoto M, Kuwayama Y; Tafluprost/Timolol Versus Latanoprost/Timolol (TTVLT) Study Group. Multicenter, Randomized, Controlled Study Comparing Tafluprost/Timolol Fixed Combination with Latanoprost/Timolol Fixed Combination in Primary Open-Angle Glaucoma and Ocular Hypertension [published correction appears in Adv Ther. 2019;36(2):492-494]. Adv Ther. 2018;35(6):796-808. https://doi.org/10.1007/s12325-018-0718-9
Lou H, Wang H, Zong Y, Cheng JW, Wei RL. Efficacy and tolerability of prostaglandin-timolol fixed combinations: an updated systematic review and meta-analysis. Curr Med Res Opin. 2015;31(6):1139-1147. https://doi.org/10.1185/03007995.2015.1039504
Rahman MQ, Montgomery DM, Lazaridou MN. Surveillance of glaucoma medical therapy in a Glasgow teaching hospital: 26 years’ experience. Br J Ophthalmol. 2009;93(12):1572-1575. https://doi.org/10.1136/bjo.2008.151522
Alm A, Schoenfelder J, McDermott J. A 5-year, multicenter, open-label, safety study of adjunctive latanoprost therapy for glaucoma. Arch Ophthalmol. 2004;122(7):957-965. https://doi.org/10.1001/archopht.122.7.957
Alm A, Grunden JW, Kwok KK. Five-year, multicenter safety study of fixed-combination latanoprost/timolol (Xalacom) for open-angle glaucoma and ocular hypertension. J Glaucoma. 2011;20(4):215-222. https://doi.org/10.1097/IJG.0b013e3181e08121
Ayub G, de Vasconcelos JPC, Costa VP. The Impact of Covid-19 in the Follow-Up of Glaucoma Patients in a Tertiary Center: A Comparison Between Pre-Pandemic and Pandemic Periods. Clin Ophthalmol. 2021;15:4381-4387. Epub 2021 Nov 3. https://doi.org/10.2147/OPTH.S334147
Diestelhorst M, Larsson LI; European-Canadian Latanoprost Fixed Combination Study Group. A 12-week, randomized, double-masked, multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components. Ophthalmology. 2006;113(1):70-76. https://doi.org/10.1016/j.ophtha.2005.06.027
Karlova EV. Latanoprost/Timolol fixed combination: Mechanism of Action and new Aspects of Clinical Practice. Russian Journal of Clinical Ophthalmology = RMZh. Klinicheskaja oftal’mologija. 2014;14(3):127-131. (In Russ.).

Close metadata